D
iabetic retinopathy is the leading cause of blindness in the working-age US population. 1 The most severe form of retinopathy, proliferative diabetic retinopathy (PDR), is defined as the growth of new blood vessels (i.e., neovascularization) on the optic nerve head and/or retina with a predilection for the major vascular arcades in the posterior pole. The natural history of neovascularization, as well as treatment with panretinal photocoagulation or intravitreal anti-vascular endothelial growth factor (VEGF) agents, results in progressive fibrosis, ultimately leading to fibrovascular membranes that can contract and cause vision-threatening traction retinal detachment (TRD). [2] [3] [4] [5] Vascular endothelial growth factor plays a critical role in the formation of neovascularization, 6, 7 whereas connective tissue growth factor (CTGF) potentiates the generation of fibrosis. 8, 9 Tipping of this balance from angiogenic to fibrotic membranes in eyes with PDR has been linked to VEGF and CTGF, respectively, and is termed the "angiofibrotic switch." 10 Studies purporting the role of these growth factors in the angiofibrotic switch were based on cross-sectional studies of aqueous and vitreous samples from eyes with PDR and varying severity of fibrovascular membranes. 9, 10 As anti-VEGF agents are given to eyes before surgery for TRD from PDR (and in eyes with PDR not needing immediate surgery 11 ) to purportedly facilitate removal of membranes by decreasing bleeding thereby decreasing complications and improving outcomes, 12 it is important to understand the biologic bases mediating the antiangiogenic and profibrotic mechanisms at the molecular and cellular levels because the former may be helpful during surgery but the latter may worsen the TRD. This might help clinicians better prevent complications from relative indiscriminate use of anti-VEGF drugs and foster development of novel agents that could allow for more precise in targeting of the right signals at the right time in eyes with PDR.
In our first report from 2012 of a randomized, double-masked controlled trial examining the effect of VEGF inhibition on vitreous levels of VEGF and CTGF in eyes with severe TRD from PDR, we found that eyes that were given bevacizumab had suppression of VEGF and had vitreous VEGF levels that correlated positively with CTGF levels. 2 Most of these eyes had advanced TRDs with membranes that were predominantly fibrotic at their preoperative baseline examination. However, 6 of the 10 eyes randomized to receive intravitreal bevacizumab 1.25 mg had mixed neovascular-fibrotic membranes preoperatively; by the time of surgery (average 4.8 days after injection), 83% of these eyes had regression of the neovascular component, leaving completely fibrotic membranes for intraoperative dissection. Nearly all eyes in both study arms had extraction of the diabetic membranes for subsequent histologic analysis to examine the effect of bevacizumab on cells and growth factors previously implicated in angiofibrosis. The goal of this study was to compare the effect of VEGF inhibition with sham treatment on these membranes vis a vis: 1) VEGF and CTGF content, 2) colocalization of these cytokines with endothelial cells (CD31), myofibroblasts (a-smooth muscle actin [SMA]), and retinal pigment epithelium (cytokeratin [CK]) markers, 3) morphologic alterations, and 4) apoptosis. It also allowed us to determine how well vitreous levels of these growth factors correlated with the amount of signal measured in their respective membranes.
Methods

Patients and Tissue Preparations
Description of the trial has been previously done and registered under www.clinicaltrials.gov NCT#01270542. Informed consent was obtained from all subjects for this study, which had institutional review board approval and adhered to the tenets of the Declaration of Helsinki. In summary, 20 Thawed tissue sections were air-dried, fixed in acetone (5 minutes), and washed with phosphatebuffered saline (pH 7.4) for 5 minutes. Sections were blocked with 1% bovine serum albumin in 1X phosphate-buffered saline for 1 hour, and then incubated with anti-human CTGF (R&D, Minneapolis, MN) or anti-VEGF (Abcam, Cambridge, MA) antibody overnight at 4°C. Sections were washed the next day and incubated with the appropriate secondary Cy5 antibody (Invitrogen, Carlsbad, CA) for 30 minutes. For double labeling, the sections were returned to 1% bovine serum albumin for 1 hour and then incubated with one of the following: anti-CD31 (Abbiotec, San Diego, CA), anti-SMA (Abcam), or anti-CK (pan-CK; Dako, Carpinteria, CA), 13 and incubated for 1 hour at room temperature. The appropriate secondary fluorescein isothiocyanate-conjugated antibody (Vector Laboratories, Burlingame, CA) was then applied for another 30 minutes. After each step of the incubation, sections were washed with phosphate-buffered saline 3 times for 5 minutes each. Sections were mounted with medium for fluorescence with DAPI (Vector), and were examined with a confocal laser scanning microscope (LSM510; Carl Zeiss Meditec, Inc, Thornwood, NY).
Automated pixel count of the intensity of VEGF, CTGF, CD31, SMA, and CK signal per standard area as well as colocalization analyses using pixel overlap was performed using Volocity software version 5.4 after thresholding. Two to four sections taken from different areas of each patient's membrane were averaged to generate each of these pixel intensity distributions.
Cell Fibrosis, Density, and Apoptosis Measurements
Representative sections (n = 2-4) from each patient's epiretinal membrane were stained with Masson trichrome to evaluate the intensity of fibrosis and vascularity in the membranes through collagen deposition with an Olympus BX41 fluorescence microscope. Each section was assigned a semiquantitative grade for amount of fibrosis, intensity of fibrosis, and vascularity from + to +++ based on morphology. Vessel density estimation was represented as the number of vessel per area of the membrane. 14 All images from each membrane were taken using an Olympus BX41 fluorescence microscope. Quantitative assessment of nucleated cell density in hematoxylin and eosin (H&E)-stained membranes was performed using "Image Analyze Menu" from Image J 15 (https://imagej. nih.gov/ij/) version 1.46n. Hematoxylin and eosinstained color images were converted to grayscale. Using a preset threshold and binary, all nucleated cells were selected based on their distinct features such as cell size, shapes, and staining features; the same threshold and binary were used for all images. The total number of nucleated cells of each image was measured automatically by running "Analyze-Analyze Particles." Similar procedures were applied to measure the area of membrane in pixels from each image ("AnalyzeMeasure Area"); areas were converted to mm 2 with a scale according to the magnification used while capturing the images. Nucleated cell density was expressed as mean number of cells per mm 2 in each membrane ± SD for each group.
Apoptosis in membranes was detected by fluorescent terminal dUTP nick-end labeling (TUNEL assay; Roche Applied Science, Indianapolis, IN). Ninemicrometer cryosections were fixed in 4% paraformaldehyde and stained for nuclear DNA fragmentation according to the manufacturer's protocol and was expressed as the number of TUNEL-positive cells per total cell nuclei in the membrane.
Fewer eyes were available for the Masson Trichrome and TUNEL stains because of varying sizes of extracted tissue (see results for n); only eyes with adequate amount of tissue were stained, counted, and analyzed. All other analyses had a minimum of nine membranes counted in each group.
Six to nine random fields from two to three sections per patient were analyzed in Image J. All estimations were performed in a masked fashion by two expert graders.
Statistical Analysis
Data were analyzed using F-test and paired Student's t-test to compare the bevacizumab group with controls. Results are expressed as mean ± SEM, and P # 0.05 was considered statistically significant. Correlation between vitreous and membrane levels of CTGF and VEGF were performed using the R statistical computing environment (R Core Team [2013] . R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; http://www.R-project.org/).
Results
Coexpression of Vascular Endothelial Growth Factor and Connective Tissue Growth Factor in diabetic membranes with CD31, Smooth Muscle Actin, and Cytokeratin
Positive staining of VEGF and CTGF was seen in all membranes (Figure 1 ) but there was no statistically significant difference seen in the bevacizumab group compared with the sham group (n for each group detailed in Table 1 and Figure 2 ).
Positive staining of VEGF, CTGF, CD31, and CK was detected in all membrane sections (Figure 1 ). Intravitreal bevacizumab given within 3 to 7 days before TRD surgery did not significantly decrease VEGF or CTGF expression in membranes, that is, eyes that received bevacizumab still expressed VEGF in membranes. Immunoreactivity intensity of CD31-CTGF and CK-VEGF in membrane sections in the preoperative bevacizumab group had a greater than 25% reduction (nonsignificant) Vitreous levels for VEGF and CTGF found from our first report 2 were compared with the levels found in membranes of the same patients; a negative correlation was found for CTGF (P = 0.049), whereas a modestly positive correlation was found for VEGF, although this relationship did not reach statistical significance (P = 0.061; Figure 2 ).
Morphometric Assessment and Cell Penetration
Based on H&E-stained histological sections, there was no difference in mean number of nucleated cells in the membranes receiving bevacizumab (316.94/mm 2 ) and controls (313.18/mm 2 ; P = 0.97; Figure 3 ). 
Assessment of Collagen Deposition by Trichrome Staining
Collagen deposition, an indicator of fibrosis, was evaluated in the membranes using Masson trichrome staining (Figure 4) . Grossly, high levels of collagen were observed in both groups. Semiquantitative assessment showed a trend toward higher intensity of collagen deposition in the bevacizumab group (bevacizumab: 0.82, 95% CI 0.72-0.89; n = 4 vs. controls 0.72, 95% CI 0.45-0.99; n = 2; P = 0.20). However, the grade of vascularity was lower (but not statistically significant) in membranes after bevacizumab (mean = 0.62, 95% CI 0.55-0.84) compared with controls (mean = 0.89, 95% CI 0.58-1.14; P = 0.15).
Detection of Apoptotic Cells by Terminal dUTP Nick-end Labeling Staining in Membranes
Despite a relatively low number of eyes with membranes adequate for analysis (due to tissue depletion from above studies), the density of TUNELpositive cells (i.e., number of TUNEL-positive cells to total DAPI-positive cells) was significantly higher (P = 0.05) in bevacizumab-treated fibrovascular membranes (20.02%, 95% CI 13.66-26.37, n = 4) compared with controls (9.75%, 95% CI 9.44-10.07; n = 2) ( Figure 5 ).
Discussion
In this randomized controlled study, we found that fibrovascular membranes from eyes with diabetic traction detachments treated with and without preoperative intravitreal bevacizumab had histologically detectable growth factors associated with angiogenesis (VEGF) and fibrosis (CTGF). Vascular endothelial growth factor levels in the vitreous published in the first report from this study using enzyme-linked immunosorbent assay were positively correlated at a modest level with VEGF in membranes of the same patients, whereas CTGF levels in vitreous were negatively correlated with CTGF content in the membranes. 2 Apoptotic cells, detected by TUNEL staining, were more numerous in eyes treated with bevacizumab compared with controls.
The utility of intravitreal bevacizumab for inducing neovascular regression in eyes with severe PDR has been demonstrated in numerous studies, 2, 3, [16] [17] [18] but the exact mechanism underlying the conversion of neovascularization to fibrosis is unclear. Previous reports have documented that fibrovascular membrane constituents include collagen, myofibroblasts, 14 abnormal vascular endothelial cells, perivascular cells, stromal cells, 19 and M2 subgroup macrophages. 20 Vitreous fluid from PDR 
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patients with membranes show elevated levels of several key cytokines involved in angiogenesis and fibrosis such as VEGF, CTGF, TGF-beta, 2,9,21-23 and sCD163. Kuiper et al have described the balance of VEGF and CTGF as having a major role in the angiofibrotic switch whereby the decreasing activity of VEGF is associated with increasing CTGF, resulting in the transformation of a membrane that is predominantly neovascular to a more fibrotic phenotype. 9, 14, 21, 22, [24] [25] [26] Thus, although administering anti-VEGF agents may decrease bleeding at surgery and perioperative complications for eyes with TRD from PDR, the angiofibrotic switch could accelerate fibrosis and worsen the TRD, putting the eye at further risk of vision loss. We previously showed that within 6 days of intravitreal bevacizumab injection, vitreous VEGF levels were significantly reduced and there was a clinically observable alteration in diabetic membranes; however, CTGF levels were unchanged. 2 Here, we quantified VEGF and CTGF in membranes extracted from the same patients, and performed colocalization studies with antibodies directed against CD31, and SMA, and CK. Kubota et al 27 also compared membranes from eyes that received bevacizumab compared with controls, and although our findings are consistent with theirs regarding similar vascular endothelial cell density between the bevacizumab and control membranes, Kubota et al 27 found that VEGF content was lower in the membranes of bevacizumab-treated eyes compared with controls. Although we had over 50% more subjects in our study compared with Kubota et al, 27 most eyes in our study (and all eyes in the control group) had completely fibrotic, avascular membranes; thus, it may be difficult to detect a difference in VEGF signal because of the already low signal in the control membranes. In addition, that VEGF membrane signal does not change with decreased vitreous VEGF after bevacizumab implies that VEGF is still being produced in these membranes. A significant change in colocalization from VEGF inhibition was not seen in CD31, SMA, or CK containing cells; thus, the inhibition of vitreous VEGF is likely because of decreased production from the retina, not the membranes. Alternatively, bevacizumab may only bind to VEGF released from cells into the vitreous and not change VEGF gene expression in PDR membranes; so, the vitreous concentration is attenuated but the VEGF membrane content is unaffected. Notably, comparison of vitreous ELISA levels for VEGF and measurement of VEGF Fig. 2 . Vascular endothelial growth factor and CTGF levels in membranes were plotted against their respective vitreous levels (log transformed). There was a modest positive correlation (but not statistically significant) between vitreous and membrane with VEGF (A) and marginal negative correlation observed with CTGF (B). *P # 0.05, which was considered statistically significant. in membranes from the same patients shows a modest positive correlation between vitreous and membrane VEGF levels.
Based on our initial report of high aqueous CTGF levels at baseline in both study groups, 2 it is not surprising that membrane CTGF levels were not different. Similarly, the colocalization of CTGF was also unaffected by bevacizumab. All cases recruited in this trial had significant fibrosis, which was confirmed by the Masson trichrome staining of membranes in our study expressing high levels of collagen content in both groups. This may explain the relative resistance of seeing a definite angiofibrotic switch from bevacizumab suggested histologically by other groups. 14 Moreover, the negative correlation between CTGF in the vitreous and extracted membranes suggests that aqueous and/or vitreous CTGF levels may not be an ideal biomarker for estimating CTGF levels in the posterior segment.
Notably, we expand on the number of cases that Kohno et al 28 reported regarding TUNEL-positive cells in membranes and found a significantly higher amount of apoptotic cells in the bevacizumab-treated eyes compared with controls, but this result should be interpreted with caution because the number of sections available for analysis was low. Vascular endothelial growth factor is known to have prosurvival effects on endothelial cells that are mediated by the phosphatidylinositol-3-kinase-Akt pathway 29 as well as expression of Bcl-2 and A1 in endothelial cells. 30 Consequently, inhibition of VEGF would downregulate these antiapoptotic mechanisms, accounting for the higher amount of apoptosis observed in the bevacizumab group. Although increased endothelial cell apoptosis in the bevacizumab group would seem to be at odds with similar expression of vascular endothelial cell marker CD31 content between the 2 groups, it is interesting to note that other groups have similarly found stable levels of endothelial cell markers despite bevacizumab. 31, 32 Alternatively, because the TUNEL stain is a general marker for apoptosis and not specific for endothelial cells, it is possible that there are downstream effects to VEGF inhibition that resulted in apoptosis of nonendothelial cells; however, this would need to be explored in further detail for confirmation. Regardless, this report supports the notion that bevacizumab inhibition induces contraction of blood vessels rather than obliteration of them. 31, 32 In conclusion, our study demonstrates that intravitreal bevacizumab at 1.25 mg administered within 1 week of surgery significantly suppresses vitreous VEGF levels, but does not significantly alter VEGF or CTGF expression in fibrotic diabetic tractional membranes. Still, because many patients with endstage PDR often have comorbidities that make them prone to cancellation on the day of surgery, we recommend judicious use only in patients who already have full medical clearance so that their surgery is not delayed past 1 to 2 weeks after anti-VEGF at which point the risk of worsening TRD increases. Bevacizumab may result in apoptosis within fibrovascular membranes but (at least in the short interval between injection and surgery) did not show a significant change in total nucleated cells or a subset of vascular endothelial cell content, myofibroblasts, or CK. Despite our sample size being small and the results, therefore, inherently limited, this study provides a unique histopathologic point of view along with correlation to ocular fluid levels from the effect of VEGF inhibition (positive for VEGF but negative for CTGF) on severe diabetic membranes due to PDR. To further confirm our preliminary findings, investigations involving a larger sample size with appropriate randomization and control group will be of value. In addition, studies that better elucidate the timing of when CTGF increases during the profibrotic aspect of the angiofibrotic switch would be useful because CTGF inhibition may have a role in reducing intraocular fibrosis.
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